Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 106, Issue 11, 2012, Pages 668-676

  Mukhopadhyay, Debanjan ^a   Das, Nilay Kanti ^b   De Sarkar, Sritama ^a   Manna, Alak ^a   Ganguly, Dwijendra Nath ^c   Barbhuiya, Joyashree Nath ^b   Maitra, Arup K ^a   Hazra, Avijit ^a   Chatterjee, Mitali ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

^c CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

Author keywords

Antileishmanial antibody; Avidity; Humoral response; Leishmaniasis; PKDL; Post kala azar dermal leishmaniasis

Indexed keywords

CD19 ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; HUMORAL IMMUNITY; INDIAN; MAJOR CLINICAL STUDY; MALE; SCHOOL CHILD; SKIN LEISHMANIASIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULINS; INDIA; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKINS; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; YOUNG ADULT;

NASO HEXACANTHUS;

EID: 84867329962     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1016/j.trstmh.2012.07.005     Document Type: Article

References (35)

1. WHO. Control of the leishmaniases. Geneva: World Health Organization; 2010. Technical Report Series No. 949.
2. Ganguly S., Das N.K., Barbhuiya J.N., Chatterjee M. Post-kala-azar dermal leishmaniasis- an overview. Int J Dermatol 2010, 49:921-931.
3. Mondal D., Singh S.P., Kumar N., et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 2009, 3:355.
4. Zilstra E.E., Musa A.M., Khalil E.A., El-Hassan I.M., El-Hassan A.M. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003, 3:87-98.
5. Rathi S.K., Pandhi K., Chopra P., Khanna N. Post-kala-azar dermal leishmaniasis: a histopathological study. Indian J Dermatol Venereol Leprol 2005, 71:250-253.
6. Ghosh A.K., Dasgupta S., Ghose A.C. Immunoglobulin G subclass-specific antileishmanial antibody responses in Indian kala-azar and post-kala-azar dermal leishmaniasis. Clin Diagn Lab Immunol 1995, 2:291-296.
7. Ansari N.A., Kumar R., Raj A., Salotra P. Elevated levels of IgG3 and IgG4 subclass in paediatric cases of kala azar. Parasite Immunol 2008, 30:403-409.
8. Musa A.M., Khalil E.A., Mahgoub F.A., Hamad S., Elkadaru A.M., El Hassan A.M. Efficacy of liposomal amphotericn B (AmBisome) in the treatment of persistent post kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol 2005, 99:563-569.
9. Ghosh S, Banerjee P, Sarkar A, Ganguly S, Datta S, Chatterjee. Co-infection of Leptomonas seymouri with Leishmania donovani in Indian Leishmaniasis. J Clin Microbiol May 2012, http:/dx.doi.org/10.1128/JCM.00966-1.
10. Chatterjee M., Basu K., Basu D., et al. Distribution of IgG subclasses in antimonial unresponsive Indian kala-azar patients. Clin Exp Immunol 1998, 114:408-413.
11. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1995, 193:265-275.
12. Snider H., Lezama-Davila C., Alexander J., Satoskar A.K. Sex hormones and modulation of immunity against leishmaniasis. Neuroimmunomodulation 2009, 16:106-113.
13. Saha S., Mondal S., Banerjee A., Ghose J., Bhowmick S., Ali N. Immune responses in kala-azar. Indian J Med Res 2006, 123:245-266.
14. Castellano L.R., Filho D.C., Argiro L., et al. Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production. Hum Immunol 2009, 70:383-390.
15. El Amin E.M., Wright E.P., Vlug A. Characterization of the humoral immune response in Sudanese leishmaniasis: specific antibody detected by class- and subclass-specific reagents. Clin Exp Immunol 1986, 64:14-19.
16. Haldar J.P., Saha K.C., Ghose A.C. Serological profiles in Indian post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 1981, 75:514-517.
17. Miles S.A., Conrad S.M., Alves R.G., Jeronimo S.M., Mosser D.M. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 2005, 201:747-754.
18. Kane M.M., Mosser D.M. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001, 166:1141-1147.
19. Elassad A.M., Younis S.A., Siddig M., Grayson J., Petersen E., Ghalib H.W. The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients. Clin Exp Immunol 1994, 95:294-299.
20. Sharma U., Singh S. Immunobiology of leishmaniasis. Indian J Exp Biol 2009, 47:412-423.
21. Salotra P., Sreenivas S., Beena K.R., Mukherjee A., Ramesh V. Parasite detection in patients with post kala-azar dermal leishmaniasis in India: a comparison between molecular and immunological methods. J Clin Pathol 2003, 56:840-843.
22. Anam K., Afrin F., Banerjee D., et al. Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy. Infect Immun 1999, 67:6663-6669.
23. Atta A.M., D'Oliveira A., Correa J., Atta M.L., Almeida R.P., Carvalho E.M. Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis. Am J Trop Med Hyg 1998, 59:426-430.
24. Cabrera M., Rodriguez O., Monsalve I., Tovar R., Hagel I. Variations in the serum levels of soluble CD23, nitric oxide and IgE across the spectrum of American cutaneous leishmaniasis. Acta Trop 2003, 88:145-151.
25. Sousa-Atta M.L., Salamé G.S., D'Oliveira A., Almeida R.P., Atta A.M., Carvalho E.M. Immunoglobulin E antileishmanial antibody response in cutaneous leishmaniasis. Clin Diagn Lab Immunol 2002, 9:101-104.
26. Saha S., Mazumdar T., Anam K., et al. Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis. J Clin Microbiol 2005, 43:1269-1277.
27. Chappuis F., Sundar S., Hailu A., et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol 2007, 5:873-882.
28. Ganguly S., Das N.K., Panja M., et al. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J Infect Dis 2008, 197:1762-1771.
29. Schultz C.L., Coffman R.L. Control of isotype switching by T cells and cytokines. Curr Opin Immunol 1994, 3:350-354.
30. +) B cells to secrete IgG1 and IgG3. J Exp Med 1994, 179:757-762.
31. + T cell clones. J Exp Med 1994, 173:747-750.
32. Kawano Y., Noma T., Yata J. Regulation of human IgG subclass production by cytokines IFN-γ and IL-6 acts antagonistically in the induction of human IgG1 but additively in the induction of IgG2. J Immunol 1994, 153:4948-4958.
33. Finkelman F.D., Holmes J., Katona I.M., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990, 8:303-333.
34. Kenney R.T., Sacks D.L., Gam A.A., Murray H.W., Sundar S. Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis 1998, 177:815-818.
35. Redhu N.S., Dey A., Balooni V., Singh S. Use of immunoglobulin g avidity to determine the course of disease in visceral and post-kala-azar dermal leishmaniasis patients. Clin Vaccine Immunol 2006, 13:969-971.